Literature DB >> 4958345

Industrial inhalation Anthrax.

P S Brachman, A F Kaufman, F G Dalldorf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 4958345      PMCID： PMC378258          DOI： 10.1128/br.30.3.646-659.1966

Source DB:  PubMed          Journal:  Bacteriol Rev        ISSN： 0005-3678


× No keyword cloud information.
  8 in total

1.  Pathogenesis of respiratory anthrax in Macaca mulatta.

Authors:  C C BERDJIS; C A GLEISER; H A HARTMEN; R W KUEHNE; W S GOCHENOUR
Journal:  Br J Exp Pathol       Date:  1962-10

2.  An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features.

Authors:  S A PLOTKIN; P S BRACHMAN; M UTELL; F H BUMFORD; M M ATCHISON
Journal:  Am J Med       Date:  1960-12       Impact factor: 4.965

3.  Experimental inhalation anthrax in the chimpanzee.

Authors:  W S ALBRINK; R J GOODLOW
Journal:  Am J Pathol       Date:  1959 Sep-Oct       Impact factor: 4.307

4.  An epidemic of inhalation anthrax: the first in the twentieth century. II. Epidemiology.

Authors:  P S BRACHMAN; S A PLOTKIN; F H BUMFORD; M M ATCHISON
Journal:  Am J Hyg       Date:  1960-07

5.  Serologic testing for anthrax antibodies in workers in a goat hair processing mill.

Authors:  P S NORMAN; J G RAY; P S BRACHMAN; S A PLOTKIN; J S PAGANO
Journal:  Am J Hyg       Date:  1960-07

6.  Industrial anthrax.

Authors:  P S BRACHMAN; F R FEKETY
Journal:  Ann N Y Acad Sci       Date:  1958-06-03       Impact factor: 5.691

7.  Airborne pulmonary tuberculosis.

Authors:  R L RILEY
Journal:  Bacteriol Rev       Date:  1961-09

8.  Field Evaluation of a Human Anthrax Vaccine.

Authors:  P S Brachman; H Gold; S A Plotkin; F R Fekety; M Werrin; N R Ingraham
Journal:  Am J Public Health Nations Health       Date:  1962-04
  8 in total
  24 in total

1.  Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Robert Bollinger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-30       Impact factor: 11.205

2.  A dynamic dose-response model to account for exposure patterns in risk assessment: a case study in inhalation anthrax.

Authors:  Bryan T Mayer; James S Koopman; Edward L Ionides; Josep M Pujol; Joseph N S Eisenberg
Journal:  J R Soc Interface       Date:  2010-11-10       Impact factor: 4.118

3.  Discussion.

Authors:  H N Glassman
Journal:  Bacteriol Rev       Date:  1966-09

Review 4.  Persistence of category A select agents in the environment.

Authors:  Ryan Sinclair; Stephanie A Boone; David Greenberg; Paul Keim; Charles P Gerba
Journal:  Appl Environ Microbiol       Date:  2007-12-07       Impact factor: 4.792

5.  The clinical aspects of anthrax.

Authors:  A B Christie
Journal:  Postgrad Med J       Date:  1973-08       Impact factor: 2.401

6.  Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Authors:  Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

7.  Inhalation anthrax: dose response and risk analysis.

Authors:  Margaret E Coleman; Brandolyn Thran; Stephen S Morse; Martin Hugh-Jones; Stacey Massulik
Journal:  Biosecur Bioterror       Date:  2008-06

Review 8.  Information on which to base assessments of risk from environments contaminated with anthrax spores.

Authors:  A Watson; D Keir
Journal:  Epidemiol Infect       Date:  1994-12       Impact factor: 2.451

9.  Pathology and pathophysiology of inhalational anthrax in a guinea pig model.

Authors:  Vladimir Savransky; Daniel C Sanford; Emily Syar; Jamie L Austin; Kevin P Tordoff; Michael S Anderson; Gregory V Stark; Roy E Barnewall; Crystal M Briscoe; Laurence Lemiale-Biérinx; Sukjoon Park; Boris Ionin; Mario H Skiadopoulos
Journal:  Infect Immun       Date:  2013-01-28       Impact factor: 3.441

10.  Epidemiologic response to anthrax outbreaks: field investigations, 1950-2001.

Authors:  Michael E Bales; Andrew L Dannenberg; Philip S Brachman; Arnold F Kaufmann; Peter C Klatsky; David A Ashford
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.